A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer

References

• Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73(6):925–933.
   PubMed Web of Science ®Google Scholar
• https://uroweb.org/individual-guidelines/oncology-guidelines/.
   Google Scholar
• Eroglu A, Ekin RG, Koc G, et al. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol. 2020;25(4):698–704.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
   PubMed Web of Science ®Google Scholar
• Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin. BJU Int. 2016;118(1):44–52.
   PubMed Web of Science ®Google Scholar
• Angulo JC, Palou J, Garcia-Tello A, et al. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette–Guerin. Actas Urol Esp. 2014;38(3):164–171.
   PubMed Web of Science ®Google Scholar
• Krajewski W, Zdrojowy R, Dembowski J, et al. The optimal timing of restaging resection before introduction of bacillus Calmette–Guerin immunotherapy in patients with high-risk non-muscle-invasive bladder cancer. Urol Int. 2019;102(1):60–68.
   PubMed Web of Science ®Google Scholar
• Grimm MO, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170(2 Pt 1):433–437.
   PubMed Web of Science ®Google Scholar
• Calo B, Chirico M, Fortunato F, et al. Is repeat transurethral resection always needed in high-grade T1 bladder cancer? Front Oncol. 2019;9:465.
   PubMed Web of Science ®Google Scholar
• Tseng WH, Liu CL, Huang SK, et al. Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience. Int Urol Nephrol. 2019;51(8):1335–1342.
   PubMed Web of Science ®Google Scholar
• Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open. 2017;7(9):e016606.
   PubMed Web of Science ®Google Scholar
• R Core team 2020. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. Available from: https://www.R-project.org/.
   Google Scholar
• Ferro M, Vartolomei MD, Cantiello F, et al. High-grade T1 on re-transurethral resection after initial high-grade T1 confers worse oncological outcomes: results of a multi-institutional study. Urol Int. 2018;101(1):7–15.
   PubMed Web of Science ®Google Scholar
• Fransen van de Putte EE, Otto W, Hartmann A, et al. Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urol Oncol. 2018;36(8):361.e7–361.e13.
   Web of Science ®Google Scholar
• Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology. 2007;70(4):758–762.
   PubMed Web of Science ®Google Scholar
• Patschan O, Holmang S, Hosseini A, et al. Second-look resection for primary stage T1 bladder cancer: a population-based study. Scand J Urol. 2017;51(4):301–307.
   PubMed Web of Science ®Google Scholar
• Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185–190.
   PubMed Web of Science ®Google Scholar
• Krajewski W, Nowak L, Poletajew S, et al. The impact of restaging transurethral resection of bladder tumour on survival parameters in T1 non-muscle invasive bladder cancer – systematic review and meta-analysis. J Endourol. 2020;34(8):795–804.
   PubMed Web of Science ®Google Scholar
• Baltaci S, Bozlu M, Yildirim A, et al. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette–Guerin. BJU Int. 2015;116(5):721–726.
   PubMed Web of Science ®Google Scholar
• Nilbert M, Blackberg M, Ceberg J, et al. Diagnostic pathway efficacy for urinary tract cancer: population-based outcome of standardized evaluation for macroscopic haematuria. Scand J Urol. 2018;52(4):237–243.
   PubMed Web of Science ®Google Scholar
• Yajima S, Yoshida S, Takahara T, et al. Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. Eur Radiol. 2019;29(7):3881–3888.
   PubMed Web of Science ®Google Scholar
• Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015;33(6):643–650.
   PubMed Web of Science ®Google Scholar
• Sorenby A, Baseckas G, Bendahl PO, et al. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients. Scand J Urol. 2019;53(2-3):109–115.
   PubMed Web of Science ®Google Scholar
• Krajewski W, Moschini M, Chorbinska J, et al. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. World J Urol. 2020. doi: 10.1007/s00345-020-03522-3.
   Web of Science ®Google Scholar